Search

In conversation with Fares Antaki: The retinal age gap in schizophrenia

Fares Antaki. Nima Ghadiri (NG): The ‘retinal age gap’ (RAG) is a relatively new concept. Based on your study [1], how confident are you in proposing this as a non-invasive, accessible biomarker for accelerated biological ageing in patients with neuropsychiatric...

Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals

Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...

Management of diabetic macular oedema in vitrectomised eyes

Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....

Guide to Gaining Approval for a Clinical Study

This article focuses on gaining approval for clinical research involving NHS patients, although the principles can be applied to other types of research. The intention is to give an overview of the requirements for setting up a research study, but...

Pathophysiology of diabetic macular oedema: why combination therapy may be better

The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...

Can 3D facial imaging improve patient management in disfiguring eye disease?

Fight for Sight is the leading UK charity funder of eye research. Since the 2013 Sight Loss and Vision Priority Setting Partnership we have encouraged our researchers to work on priorities jointly identified by people affected by sight loss and...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

The history of ophthalmology: John Argyll Robertson and Douglas Moray Cooper Lamb Argyll Robertson

The author shares the story of an extraordinary father and son, two of the major figures in defining the specialty of ophthalmology as we know it today. The renowned Glasgow Surgeon Peter Lowe described ophthalmic surgery in his legendary surgical...

Redeployment during the COVID-19 pandemic: personal accounts from four ophthalmology trainees

We once believed that the coronavirus would not penetrate the safe confines of the United Kingdom, like so many outbreaks before this. Once the news came that this pandemic descended into our hospitals, the anxieties about redeployment began. Many of...